Role of mutations in dihydrofolate reductase DfrA (Rv2763c) and thymidylate synthase ThyA (Rv2764c) in Mycobacterium tuberculosis drug resistance.
作者信息
Köser Claudio U, Veerapen-Pierce Richard N, Summers David K, Archer John A C
出版信息
Antimicrob Agents Chemother. 2010 Oct;54(10):4522-3; author reply 5423-5. doi: 10.1128/AAC.00422-10.
Abstract
摘要
相似文献
1
Role of mutations in dihydrofolate reductase DfrA (Rv2763c) and thymidylate synthase ThyA (Rv2764c) in Mycobacterium tuberculosis drug resistance.
Antimicrob Agents Chemother. 2010 Oct;54(10):4522-3; author reply 5423-5. doi: 10.1128/AAC.00422-10.
2
Role of the dihydrofolate reductase DfrA (Rv2763c) in trimethoprim-sulfamethoxazole (co-trimoxazole) resistance in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2010 Nov;54(11):4951-2; author reply 4952. doi: 10.1128/AAC.00876-10.
3
[Mutations in the thymidylate synthase gene is a major mechanism in the para-aminosalicylic acid resistance of M. tuberculosis].
Zhonghua Jie He He Hu Xi Za Zhi. 2007 Sep;30(9):683-5.
4
Coregulation of dihydrofolate reductase and thymidylate synthase B in bacillus subtilis.
Biochim Biophys Acta. 1985 Feb 20;824(2):99-103. doi: 10.1016/0167-4781(85)90085-5.
5
Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
Antimicrob Agents Chemother. 2010 Sep;54(9):3776-82. doi: 10.1128/AAC.00453-10. Epub 2010 Jun 21.
6
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2009 May;53(5):2100-9. doi: 10.1128/AAC.01197-08. Epub 2009 Feb 23.
7
E84G mutation in dihydrofolate reductase from drug resistant strains of Mycobacterium tuberculosis (Mumbai, India) leads to increased interaction with Trimethoprim.
Int J Mycobacteriol. 2015 Jun;4(2):97-103. doi: 10.1016/j.ijmyco.2015.02.001. Epub 2015 Mar 13.
8
Mycobacterium tuberculosis thymidylate synthase gene thyX is essential and potentially bifunctional, while thyA deletion confers resistance to p-aminosalicylic acid.
Microbiology (Reading). 2012 Feb;158(Pt 2):308-318. doi: 10.1099/mic.0.053983-0. Epub 2011 Oct 27.
9
Construction of a fol mutant strain of Escherichia coli for use in dihydrofolate reductase mutagenesis experiments.
J Bacteriol. 1988 Jul;170(7):3301-4. doi: 10.1128/jb.170.7.3301-3304.1988.
10
Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum.
Mol Biochem Parasitol. 1995 Jan;69(1):135-8. doi: 10.1016/0166-6851(94)00207-4.
引用本文的文献
1
Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations.
Ann Clin Microbiol Antimicrob. 2022 Nov 5;21(1):48. doi: 10.1186/s12941-022-00537-z.
2
Methodological and Clinical Aspects of the Molecular Epidemiology of Mycobacterium tuberculosis and Other Mycobacteria.
Clin Microbiol Rev. 2016 Apr;29(2):239-90. doi: 10.1128/CMR.00055-15.
3
Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance.
Antimicrob Agents Chemother. 2012 Dec;56(12):6080-7. doi: 10.1128/AAC.01641-12. Epub 2012 Sep 24.
本文引用的文献
1
Towards the understanding of resistance mechanisms in clinically isolated trimethoprim-resistant, methicillin-resistant Staphylococcus aureus dihydrofolate reductase.
J Struct Biol. 2010 Apr;170(1):93-7. doi: 10.1016/j.jsb.2009.12.011. Epub 2009 Dec 21.
2
Genomic diversity among drug sensitive and multidrug resistant isolates of Mycobacterium tuberculosis with identical DNA fingerprints.
PLoS One. 2009 Oct 12;4(10):e7407. doi: 10.1371/journal.pone.0007407.
3
Reconsidering some approved antimicrobial agents for tuberculosis.
Antimicrob Agents Chemother. 2009 Nov;53(11):4577-9. doi: 10.1128/AAC.00887-09. Epub 2009 Sep 8.
4
Contribution of dfrA and inhA mutations to the detection of isoniazid-resistant Mycobacterium tuberculosis isolates.
Antimicrob Agents Chemother. 2009 Sep;53(9):4010-2. doi: 10.1128/AAC.00433-09. Epub 2009 Jul 6.
5
Tuberculosis and trimethoprim-sulfamethoxazole.
Antimicrob Agents Chemother. 2009 Nov;53(11):4789-93. doi: 10.1128/AAC.01658-08. Epub 2009 Jun 29.
6
Analysis of mutational resistance to trimethoprim in Staphylococcus aureus by genetic and structural modelling techniques.
J Antimicrob Chemother. 2009 Jun;63(6):1112-7. doi: 10.1093/jac/dkp090. Epub 2009 Apr 21.
7
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2009 May;53(5):2100-9. doi: 10.1128/AAC.01197-08. Epub 2009 Feb 23.
8
Staphylococcus aureus as an intracellular pathogen: the role of small colony variants.
Trends Microbiol. 2009 Feb;17(2):54-8. doi: 10.1016/j.tim.2008.11.004. Epub 2009 Jan 21.
9
Biochemical and structural characterization of the putative dihydropteroate synthase ortholog Rv1207 of Mycobacterium tuberculosis.
FEMS Microbiol Lett. 2008 Oct;287(1):128-35. doi: 10.1111/j.1574-6968.2008.01302.x. Epub 2008 Aug 1.
10
The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates.
Antimicrob Agents Chemother. 2008 Jun;52(6):2183-9. doi: 10.1128/AAC.01395-07. Epub 2008 Mar 31.
Zotero 插件